Tenaya Therapeutics publishes preclinical data on heart disease in Circulation

Tenaya Therapeutics “announced the publication of preclinical research in the October 3, 2023 issue of the American Heart Association’s journal, Circulation. The article, titled “Improved Cardiac Function in Postischemic Rats Using an Optimized Cardiac Reprogramming Cocktail Delivered in a Single Novel Adeno-Associated Virus,” details Tenaya’s initial success in cardiac cellular regeneration utilizing a single adeno-associated viral vector to deliver specific combinations of genes to reprogram cells in the heart following ischemic injury. An estimated four million people in the U.S. are living with heart failure associated with a prior heart attack, or myocardial infarction. When an MI occurs, cardiomyocytes, the heart cells responsible for contraction, are lost, while cardiac fibroblasts, the heart cells that form connective tissue, multiply and contribute to the formation of scar tissue and fibrosis. The loss of CMs following MI permanently impairs heart contraction, leading to heart failure and potentially fatal arrhythmias, and is estimated to result in the death of approximately 5% to 10% of heart attack survivors within the first year. There are currently no approved treatments that address the underlying loss of heart tissue.”